Impact of the major BCR-ABL1 transcript type on clinical and biological parameters and molecular response in patients with chronic myeloid leukemia | Zendy

Mourad Nachi | Zendy; Ibtissem Kihel | Zendy; B Entasoltane | Zendy; Mohamed Brahimi | Zendy; Nabil Yafour | Zendy; Djaoued Guella | Zendy; Amine Abed | Zendy; Mohamed Amine Bekadja | Zendy

Open Access

Impact of the major BCR-ABL1 transcript type on clinical and biological parameters and molecular response in patients with chronic myeloid leukemia

Author(s) -

Mourad Nachi,

Ibtissem Kihel,

B Entasoltane,

Mohamed Brahimi,

Nabil Yafour,

Djaoued Guella,

Amine Abed,

Mohamed Amine Bekadja

Publication year - 2020

Publication title -

hematology/oncology and stem cell therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.666

H-Index - 22

eISSN - 1658-3876

pISSN - 2589-0646

DOI - 10.1016/j.hemonc.2020.08.003

Subject(s) - myeloid leukemia , medicine , cumulative incidence , imatinib , oncology , leukemia , gastroenterology , real time polymerase chain reaction , immunology , cohort , biology , gene , genetics

In chronic myeloid leukemia (CML), the impact of MBCR-ABL1 major transcript type on disease phenotype and response to treatment still controversial to date. This work aims to study the influence of Mb3a2 and Mb2a2 transcripts on clinico-biological parameters and the molecular response in patients with chronic phase chronic myeloid leukemia (CP-CML) treated with Imatinib as frontline therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research